TEL/PDGFβR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins

Experimental Hematology

Volumn 28, Issue 5, 2000, Pages 584-593

  Wilbanks, Alyson M ^a   Mahajan, Sudipta ^c   Frank, David A ^c   Druker, Brian J ^d   Gilliland, D Gary ^a,b   Carroll, Martin ^a  

^a Dept of Hematology and Oncology ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CMML; STAT5; TEL PDGF R; Tyrosine kinases

Indexed keywords

HYBRID PROTEIN; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT5 PROTEIN; DNA BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 3; MILK PROTEIN; PHOSPHOPROTEIN; PHOSPHOTYROSINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT INTERFERON; REPRESSOR PROTEIN; STAT1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV6;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CELL TRANSFORMATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL LINE; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION;

CELL LINE; CELL LINE, TRANSFORMED; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-2; INTERLEUKIN-3; MILK PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0033625358     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00138-7     Document Type: Article

References (53)

1. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:1985;550.
2. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307.
3. Golub T.R., Goga A., Barker G.et al. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol Cell Biol. 16:1996;4107.
4. Lacronique V., Boureux A., Valle V.D.et al. A TEL/JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 278:1997;1309.
5. Ross T.S., Bernard O.A., Berger R., Gilliland D.G. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 91:1998;4419.
6. Morris S.W., Kirstein M.N., Valentine M.B.et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hogkin's lymphoma. Science. 263:1994;1281.
7. Xiao S., Nalabolu S.R., Aster J.C.et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 18:1998;84.
8. Wasylyk B., Hahn S.L., Giovane A. The Ets family of transcription factors. Eur J Biochem. 211:1993;7.
9. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Sci U S A. 93:1996;14845.
10. Sattler M., Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 8:1997;63.
11. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 269:1994;32023.
12. Drummond-Barbosa D., Vaillancourt R.R., Kazlauskas A., DiMaio D. Ligand-independent activation of the platelet-derived growth factor β receptor. requirements for bovine papillomavirus E5-induced mitogenic signalling Mol Cell Biol. 15:1995;2570.
13. Darnell J.E. STATs and gene regulation. Science. 277:1997;1630.
14. Ihle J.N., Nosaka T., Thierfelder W., Quelle F.W., Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 15:1997;105.
15. Vignais M.L., Sadowski H.B., Watling D., Rogers N.C., Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 16:1996;1759.
16. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:1996;443.
17. Meraz M.A., White J.M., Sheehan K.C.et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84:1996;431.
18. Kaplan M.H., Sun Y.L., Hoey T., Grusby M.J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 382:1996;174.
19. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 4:1996;313.
20. Thierfelder W.E., van Deursen J.M., Yamamoto K.et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 382:1996;171.
21. Takeda K., Tanaka T., Shi W.et al. Essential role of Stat6 in IL-4 signalling. Nature. 380:1996;627.
22. Shimoda K., van Deursen J., Sangster M.Y.et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 380:1996;630.
23. Teglund S., McKay C., Schuetz E.et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:1998;841.
24. Socolovsky M., Fallon A.E., Wang S., Brugnara C., Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice. a direct role for Stat5 in Bcl-X(L) induction Cell. 98:1999;181.
25. Xu X., Kang S.H., Heidenreich O., Okerholm M., O'Shea J.J., Nerenberg M.I. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest. 96:1995;1548.
26. Meydan N., Grunberger T., Dadi H.et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:1996;645.
27. Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 100:1997;3140.
28. Gouilleux-Gruart V., Gouilleux F., Desaint C.et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 87:1996;1692.
29. Chai S.K., Nichols G.L., Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 159:1997;4720.
30. Peeters P., Raynaud S.D., Cools J.et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 90:1997;2535.
31. Nieborowska-Skorska M., Wasik M.A., Slupianek A.et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 189:1999;1229.
32. Ilaria R.L. Jr., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 271:1996;31704.
33. Palacios R., Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 41:1985;727.
34. Rock K.L., Benacerraf B. Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers. IL. Competitive inhibition of I-E- restricted, antigen-specific T cell responses. J Exp Med. 160:1984;1864.
35. Muller M., Brisco J., Laxton C.et al. The protein tyrosine kinase JAK1 complements defects in interferon α/β and γ signal transduction. Nature. 366:1993;129.
36. Frank D.A., Robertson M.J., Bonni A., Ritz J., Greenberg M.E. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A. 92:1995;7779.
37. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475.
38. Sattler M., Durstin M.A., Frank D.A.et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 23:1995;1040.
39. Wakao H., Gouilleux F., Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 14:1995;854.
40. Buchdunger E., Zimmermann J., Mett H.et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a novel tyrosine protein kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A. 92:1995;2558.
41. Buchdunger E., Zimmermann J., Mett H.et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100.
42. Carroll M., Ohno-Jones S., Tamura S.et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 90:1997;4947.
43. Okuda K., Golub T.R., Gilliland D.G., Griffin J.D. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 13:1996;1147.
44. Golub T.R., Barker G.F., Bohlander S.K.et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 92:1995;4917.
45. Cao X., Tay A., Guy G.R., Tan Y.H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 16:1996;1595.
46. Jia R., Hanafusa H. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J Biol Chem. 269:1994;1839.
47. Zong C., Yan R., August A., Darnell J.E. Jr., Hanafusa H. Unique signal transduction of Eyk. constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase EMBO J. 15:1996;4515.
48. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 183:1996;811.
49. Valgeirsdottir S., Paukku K., Silvennoinen O., Heldin C.H., Claesson-Welsh L. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites on PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene. 16:1998;505.
50. Frank D.A., Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 10:1996;1724.
51. Atfi A., Prunier C., Mazars A.et al. The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. Oncogene. 18:1999;3878.
52. Besancon F., Atfi A., Gespach C., Cayre Y.E., Bourgeade M.F. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein. Proc Natl Acad Sci U S A. 95:1998;8081.
53. Onishi M., Nosaka T., Misawa K.et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 18:1998;3871.